CORCEPT THERAPEUTICS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
Mailing Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
Phone
650.688.8803
Fiscal Year End
1231
EIN
770487658
Financial Overview
FY2025
$188.85M
Total Liabilities
$679.59M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
Material Events
8-K
Legal Issue
February 19, 2026
High Impact
- CORCEPT THERAPEUTICS INC faced a significant setback in a crucial patent dispute concerning its drug Korlym®.
- The United States Court of Appeals for the Federal Circuit ruled that Teva Pharmaceuticals' generic version does not infringe two of Corcept's method-of-use patents.
8-K
Other
December 31, 2025
High Impact
- The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for CORCEPT THERAPEUTICS INC's new drug, relacorilant.
- Relacorilant was being considered as a treatment for patients with hypertension secondary to hypercortisolism.
Insider Trading
STRONG SELL
3 insiders
9 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.